European Commission grants Approval for expanded Indication of Pembrolizumab (KEYTRUDA (R)) in adult and pediatric Patients with relapsed or refractory classical Hodgkin Lymphoma-MedSci.cn

European Commission grants Approval for expanded Indication of Pembrolizumab (KEYTRUDA (R)) in adult and pediatric Patients with relapsed or refractory classical Hodgkin Lymphoma

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2021; 44 (5):

科室
- - 订阅+
  - 更多科室
工具
服务